Allyx Therapeutics is a clinical-stage biotechnology company that develops therapies to reverse neurodegeneration.
Allyx Therapeutics has raised $26.5M in total funding. The most recent round was Series B. The last funding was announced in May 2026.
Allyx Therapeutics's investors include Connecticut Innovations, Bristol-Myers Squibb, Elm Street Ventures, Spring Mountain Capital, National Institutes of Health.
Allyx Therapeutics is headquartered in New Haven, United States.
Allyx Therapeutics is a clinical-stage biotechnology company that develops therapies to reverse neurodegeneration.
Allyx Therapeutics is at the Series B stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Allyx Therapeutics — Funding & Investors." VCBacked, May 1, 2026, https://www.vcbacked.co/company/allyx-therapeutics. Accessed September 9, 2026.
VCBacked. (2026). Allyx Therapeutics — Funding & Investors. Retrieved September 9, 2026, from https://www.vcbacked.co/company/allyx-therapeutics
{{cite web |title=Allyx Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/allyx-therapeutics |website=VCBacked |access-date=September 9, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated